Amongst top therapies Anti-Infectives, Cardiac, GI, anti-diabetic and VMN grew 14.2%, 13.3%, 11.5%, 9.6% and 9.2% YoY in Jul-21. Increased pace of vaccination and slowing of wave-2 of Covid-19 led to normalised IPM growth month-on-month. Growth maintained the momentum in Jul'21 with strong contribution from high growth therapies influenced by COVID products. The key reasons for such growth are (i) increased percentage of vaccinated population with more players entering into COVID vaccine segment (ii) ease in travel restriction and less likelihood of another...